T790M
· 5 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | T790M | “DISCUSSION: They target the mutant-EGFR to overcome the tertiary resistant mutations (Del19/T790M/C797S), which represent a major clinical challenge against other Tyrosine Kinase Inhibitors (TKIs).” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFRL858R/T790M Mutations.” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “Frequency of Epidermal Growth Factor Receptor and T790M Mutations Among Patients With Non-Small Cell Lung Carcinoma: A Hospital-Based Study in the King Khalid University Hospital (KKUH) Since 2009-2017.” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “Olmutinib was approved in South Korea in May 2016 for the treatment of patients suffering from locally advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “Four cases of T790M mutations were reported for the first time among HNSCC patients.” | 0.82 | literature_variant_regex_v2 |